{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T08:50:50Z","timestamp":1767084650830,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.cyto.2018.06.006","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T23:55:10Z","timestamp":1529366110000},"page":"154439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["IL-15 and IFN-\u03b3 signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling"],"prefix":"10.1016","volume":"124","author":[{"given":"Fatemeh","family":"Vahedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne V.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Lusty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branson","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisha","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl D.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney S.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Mossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali A.","family":"Ashkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cyto.2018.06.006_b0005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jiph.2015.05.004","article-title":"The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine","volume":"9","author":"Stasi","year":"2016","journal-title":"J. Infect. Public Health"},{"issue":"1","key":"10.1016\/j.cyto.2018.06.006_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(03)00088-3","article-title":"Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C","volume":"59","author":"Pawlotsky","year":"2003","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.cyto.2018.06.006_b0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.15403\/jgld-1284","article-title":"Benefits of curing hepatitis C infection","volume":"23","author":"Marinho","year":"2014","journal-title":"J. Gastrointestin Liver Dis."},{"issue":"8","key":"10.1016\/j.cyto.2018.06.006_b0020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/gene.2015.38","article-title":"Polymorphisms in EGFR and IL28B are associated with spontaneous clearance in an HCV-infected Iranian population","volume":"16","author":"Carapito","year":"2015","journal-title":"Genes Immun."},{"issue":"5","key":"10.1016\/j.cyto.2018.06.006_b0025","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10620-012-2486-8","article-title":"Racial\/ethnic differences in spontaneous HCV clearance in HIV infected and uninfected women","volume":"58","author":"Sarkar","year":"2013","journal-title":"Dig. Dis. Sci."},{"issue":"7","key":"10.1016\/j.cyto.2018.06.006_b0030","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/gut.52.7.1030","article-title":"Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance","volume":"52","author":"Mazzeo","year":"2003","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cyto.2018.06.006_b0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1189\/jlb.4RI0214-126R","article-title":"Immune control and failure in HCV infection\u2013tipping the balance","volume":"96","author":"Dustin","year":"2014","journal-title":"J. Leukoc. Biol."},{"issue":"12","key":"10.1016\/j.cyto.2018.06.006_b0040","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2893.2008.01051.x","article-title":"Primary hepatocytes as targets for Hepatitis C virus replication","volume":"15","author":"Farquhar","year":"2008","journal-title":"J. Viral Hepatitis"},{"issue":"49","key":"10.1016\/j.cyto.2018.06.006_b0045","doi-asserted-by":"crossref","first-page":"17539","DOI":"10.1073\/pnas.0509221102","article-title":"Interfering with interferons: Hepatitis C virus counters innate immunity","volume":"102","author":"Freundt","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.cyto.2018.06.006_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/088282402317340189","article-title":"Type I interferons (IFN) are essential mediators of innate and specific immunity against viruses","volume":"15","author":"Williams","year":"2002","journal-title":"Viral Immunol."},{"key":"10.1016\/j.cyto.2018.06.006_b0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.coi.2016.06.009","article-title":"Innate immunity against hepatitis C virus","volume":"42","author":"Xu","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"10 Suppl. 2","key":"10.1016\/j.cyto.2018.06.006_b0060","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S1542-3565(05)00702-0","article-title":"Natural killer cells in hepatitis C virus infection: from innate immunity to adaptive immunity","volume":"3","author":"Takehara","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cyto.2018.06.006_b0065","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu. Rev. Immunol."},{"issue":"Pt 8","key":"10.1016\/j.cyto.2018.06.006_b0070","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J. Cell Sci."},{"issue":"10","key":"10.1016\/j.cyto.2018.06.006_b0075","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s000180050240","article-title":"Type I interferons: expression and signalization","volume":"54","author":"Doly","year":"1998","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.cyto.2018.06.006_b0080","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.apsb.2014.06.010","article-title":"Recent advances in the anti-HCV mechanisms of interferon","volume":"4","author":"Huang","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"issue":"7053","key":"10.1016\/j.cyto.2018.06.006_b0085","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cyto.2018.06.006_b0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/CMR.00010-06","article-title":"Viral determinants of resistance to treatment in patients with hepatitis C","volume":"20","author":"Wohnsland","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"issue":"5 Suppl. 1","key":"10.1016\/j.cyto.2018.06.006_b0095","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/hep.1840360716","article-title":"Optimal therapy of hepatitis C","volume":"36","author":"Di Bisceglie","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cyto.2018.06.006_b0100","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1189\/jlb.0304197","article-title":"Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis","volume":"76","author":"Ahmad","year":"2004","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.cyto.2018.06.006_b0105","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2013.04.022","article-title":"IFN-gamma production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells","volume":"59","author":"Zhang","year":"2013","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.cyto.2018.06.006_b0110","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4110\/in.2013.13.5.168","article-title":"The natural killer cell response to HCV infection","volume":"13","author":"Ahlenstiel","year":"2013","journal-title":"Immun. Net."},{"issue":"2","key":"10.1016\/j.cyto.2018.06.006_b0115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2016.03.016","article-title":"Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C *03:04 and modulate NK cell function","volume":"65","author":"Lunemann","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cyto.2018.06.006_b0120","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3389\/fmicb.2015.01061","article-title":"NK cell function and receptor diversity in the context of HCV infection","volume":"6","author":"Gardiner","year":"2015","journal-title":"Front. Microbiol."},{"issue":"21","key":"10.1016\/j.cyto.2018.06.006_b0125","doi-asserted-by":"crossref","first-page":"11148","DOI":"10.1128\/JVI.76.21.11148-11154.2002","article-title":"Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons","volume":"76","author":"Cheney","year":"2002","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.cyto.2018.06.006_b0130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1046\/j.1365-2249.2001.01468.x","article-title":"Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C","volume":"123","author":"Bergamini","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cyto.2018.06.006_b0135","article-title":"Association of TNF-alpha (-308 A\/G) and IFN-gamma (+874 A\/T) gene polymorphisms in response to spontaneous and treatment induced viral clearance in HCV infected multitransfused thalassemic patients","author":"Biswas","year":"2017","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.cyto.2018.06.006_b0140","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.4049\/jimmunol.1300164","article-title":"Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions","volume":"191","author":"Holder","year":"2013","journal-title":"J. Immunol."},{"issue":"38","key":"10.1016\/j.cyto.2018.06.006_b0145","doi-asserted-by":"crossref","first-page":"35280","DOI":"10.1074\/jbc.M105995200","article-title":"Altered regulation of ERK1b by MEK1 and PTP-SL and modified Elk1 phosphorylation by ERK1b are caused by abrogation of the regulatory C-terminal sequence of ERKs","volume":"276","author":"Yung","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cyto.2018.06.006_b0150","article-title":"Hepatitis C virus: propagation, quantification, and storage","volume":"15","author":"Yi","year":"2010","journal-title":"Curr. Protocol. Microbiol. Chap."},{"issue":"10","key":"10.1016\/j.cyto.2018.06.006_b0155","doi-asserted-by":"crossref","first-page":"e76781","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cyto.2018.06.006_b0160","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1128\/JVI.75.2.750-758.2001","article-title":"Herpes simplex virus triggers and then disarms a host antiviral response","volume":"75","author":"Mossman","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.cyto.2018.06.006_b0165","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12931-014-0164-4","article-title":"Regulation of IL-17A responses in human airway smooth muscle cells by Oncostatin M","volume":"16","author":"Kwofie","year":"2015","journal-title":"Respir. Res."},{"issue":"9956","key":"10.1016\/j.cyto.2018.06.006_b0170","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cyto.2018.06.006_b0175","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1055\/s-0034-1371008","article-title":"Interferon-combination strategies for the treatment of chronic hepatitis C","volume":"34","author":"Aronsohn","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.cyto.2018.06.006_b0180","first-page":"CD005441","article-title":"Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C","volume":"2","author":"Hauser","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cyto.2018.06.006_b0185","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/HMER.S41127","article-title":"Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents","volume":"6","author":"Kamal","year":"2014","journal-title":"Hepatic Med.: Evid. Res."},{"issue":"10","key":"10.1016\/j.cyto.2018.06.006_b0190","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat. Gene."},{"issue":"4","key":"10.1016\/j.cyto.2018.06.006_b0195","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2893.2001.00292.x","article-title":"African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians","volume":"8","author":"Kinzie","year":"2001","journal-title":"J. Viral. Hepat."},{"issue":"4","key":"10.1016\/j.cyto.2018.06.006_b0200","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1440-1746.2002.02777.x","article-title":"Hepatitis C advances in antiviral therapy: what is accepted treatment now?","volume":"17","author":"McHutchison","year":"2002","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.cyto.2018.06.006_b0205","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1189\/jlb.4MR0314-141R","article-title":"Innate immune cell networking in hepatitis C virus infection","volume":"96","author":"Saha","year":"2014","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.cyto.2018.06.006_b0210","doi-asserted-by":"crossref","first-page":"e8761","DOI":"10.1371\/journal.pone.0008761","article-title":"Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination","volume":"5","author":"Scott-Algara","year":"2010","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.cyto.2018.06.006_b0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3349\/ymj.2010.51.1.9","article-title":"Intrinsic cellular defenses against virus infection by antiviral type I interferon","volume":"51","author":"Boo","year":"2010","journal-title":"Yonsei Med. J."},{"issue":"5","key":"10.1016\/j.cyto.2018.06.006_b0220","doi-asserted-by":"crossref","first-page":"e1004128","DOI":"10.1371\/journal.ppat.1004128","article-title":"Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents","volume":"10","author":"Xiao","year":"2014","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.cyto.2018.06.006_b0225","doi-asserted-by":"crossref","first-page":"e1001184","DOI":"10.1371\/journal.ppat.1001184","article-title":"Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines","volume":"6","author":"Sene","year":"2010","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.cyto.2018.06.006_b0230","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.immuni.2006.08.009","article-title":"Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors","volume":"25","author":"Honda","year":"2006","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.cyto.2018.06.006_b0235","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1128\/JVI.01984-12","article-title":"Epigenetic silencing of antiviral genes renders clones of Huh-7 cells permissive for hepatitis C virus replication","volume":"87","author":"Chen","year":"2013","journal-title":"J. Virol."},{"issue":"2\u20133","key":"10.1016\/j.cyto.2018.06.006_b0240","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.imlet.2003.11.015","article-title":"IL-15 induces IFN-beta and iNOS gene expression, and antiviral activity of murine macrophage RAW 264.7 cells","volume":"91","author":"Liu","year":"2004","journal-title":"Immunol. Lett."},{"issue":"12","key":"10.1016\/j.cyto.2018.06.006_b0245","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.4049\/jimmunol.164.12.6244","article-title":"IL-2 activation of NK cells: involvement of MKK1\/2\/ERK but not p38 kinase pathway","volume":"164","author":"Yu","year":"2000","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2018.06.006_b0250","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/80859","article-title":"Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells","volume":"1","author":"Jiang","year":"2000","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.cyto.2018.06.006_b0255","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.bbamcr.2006.10.005","article-title":"The MEK\/ERK cascade: from signaling specificity to diverse functions","volume":"1773","author":"Shaul","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.cyto.2018.06.006_b0260","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/ncb822","article-title":"Molecular interpretation of ERK signal duration by immediate early gene products","volume":"4","author":"Murphy","year":"2002","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.cyto.2018.06.006_b0265","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2015.11.027","article-title":"Bromodomain containing protein represses the Ras\/Raf\/MEK\/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection","volume":"371","author":"Zhang","year":"2016","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.cyto.2018.06.006_b0270","doi-asserted-by":"crossref","first-page":"e7498","DOI":"10.1371\/journal.pone.0007498","article-title":"Up-regulation of hepatitis C virus replication and production by inhibition of MEK\/ERK signaling","volume":"4","author":"Ndjomou","year":"2009","journal-title":"PloS One"},{"key":"10.1016\/j.cyto.2018.06.006_b0275","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M116.727081","article-title":"Hepatitis C Virus nonstructural 5A protein interacts with Abelson interactor 1 and modulates epidermal growth factor-mediated MEK\/ERK signaling pathway","author":"Huynh","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.cyto.2018.06.006_b0280","doi-asserted-by":"crossref","first-page":"e0133264","DOI":"10.1371\/journal.pone.0133264","article-title":"HCV NS5A up-regulates COX-2 expression via IL-8-mediated activation of the ERK\/JNK MAPK pathway","volume":"10","author":"Chen","year":"2015","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.cyto.2018.06.006_b0285","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s12013-012-9505-4","article-title":"Interaction of L-SIGN with hepatitis C virus envelope protein E2 up-regulates Raf-MEK-ERK pathway","volume":"66","author":"Zhao","year":"2013","journal-title":"Cell Biochem. Biophys."},{"issue":"4","key":"10.1016\/j.cyto.2018.06.006_b0290","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12192-013-0405-3","article-title":"ERK signaling is triggered by hepatitis C virus E2 protein through DC-SIGN","volume":"18","author":"Zhao","year":"2013","journal-title":"Cell Stress Chaperones"},{"issue":"2","key":"10.1016\/j.cyto.2018.06.006_b0295","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.antiviral.2012.09.002","article-title":"Interference with ERK and STAT signaling pathways and inhibition of hepatitis C virus replication by ribavirin","volume":"96","author":"Zhao","year":"2012","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.cyto.2018.06.006_b0300","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cyto.2014.11.031","article-title":"Involvement of ERK pathway in interferon alpha-mediated antiviral activity against hepatitis C virus","volume":"72","author":"Zhao","year":"2015","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.cyto.2018.06.006_b0305","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s12250-012-3257-6","article-title":"Regulation of hepatitis C virus replication and gene expression by the MAPK-ERK pathway","volume":"27","author":"Pei","year":"2012","journal-title":"Virol. Sin."},{"issue":"6","key":"10.1016\/j.cyto.2018.06.006_b0310","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000321452","article-title":"Bile acids promote HCV replication through the EGFR\/ERK pathway in replicon-harboring cells","volume":"54","author":"Patton","year":"2011","journal-title":"Intervirology"},{"issue":"2","key":"10.1016\/j.cyto.2018.06.006_b0315","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1189\/jlb.0106014","article-title":"Up-regulation of ERK and p38 MAPK signaling pathways by hepatitis C virus E2 envelope protein in human T lymphoma cell line","volume":"80","author":"Zhao","year":"2006","journal-title":"J. Leukoc. Biol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466618302540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466618302540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:53:11Z","timestamp":1760907191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466618302540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":63,"alternative-id":["S1043466618302540"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2018.06.006","relation":{},"ISSN":["1043-4666"],"issn-type":[{"type":"print","value":"1043-4666"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-15 and IFN-\u03b3 signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2018.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154439"}}